EP 05 — Upwest, Kupando, ESG Funds vs. Reality
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
EP 05 — Upwest, Kupando, ESG Funds vs. Reality
-
Narrated by:
-
Written by:
In this episode, we roast two European startups and three investment funds — and end up noticing that most of what's being funded right now isn't startups at all. Upwest (Berlin) wants to be the investment operating system for legacy banks, but AI is collapsing the very complexity they're paid to abstract away. Kupando (Schönefeld) is betting on innate immunity therapy KUP101 for cases where standard immunotherapy fails — biotech plays by completely different investment rules, and that's worth understanding. We also briefly cover Partech Impact Fund, Montis VC, and Homaio: three ESG-flavored vehicles where the real story is about choosing sides, not backing innovation.
adbl_web_anon_alc_button_suppression_c
No reviews yet